BiotechTube

BGS649

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypogonadotropic Hypogonadism

Conditions

Hypogonadotropic Hypogonadism

Trial Timeline

Nov 15, 2016 → Nov 21, 2018

NCT ID
NCT02908074

About BGS649

BGS649 is a phase 2 stage product being developed by Mereo BioPharma for Hypogonadotropic Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT02908074. Target conditions include Hypogonadotropic Hypogonadism.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02908074Phase 2Completed

Competing Products

3 competing products in Hypogonadotropic Hypogonadism

See all competitors
ProductCompanyStageHype Score
Investigational new drug company code: BGS649 + PlaceboNovartisPhase 2
52
Corifollitropin alfa + hCGOrganonPhase 3
72
BGS649 + PlaceboMereo BioPharmaPhase 2
44

Other Products from Mereo BioPharma

Alvelestat (MPH966)Phase 2
44
BCT197 + PlaceboPhase 2
44
Pemetrexed + Carboplatin + demcizumabPhase 2
44
Nivolumab + EtigilimabPhase 2
44
BGS649 + PlaceboPhase 2
44